{"id":"rapid-tapering-glucocorticoids-inebilizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Hyperglycemia / glucose intolerance"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Mood disturbances"},{"rate":null,"effect":"Immunosuppression-related complications"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Inebilizumab binds to BDCA-2 on plasmacytoid dendritic cells, depleting these cells and reducing their production of type I interferons and support for autoreactive B cells. Glucocorticoids provide rapid anti-inflammatory and immunosuppressive effects during the acute phase. Together, this combination targets both innate immune activation and adaptive autoimmune responses.","oneSentence":"Inebilizumab, a monoclonal antibody targeting plasmacytoid dendritic cells (pDCs), reduces pathogenic B cell and autoantibody production, combined with rapid-tapering glucocorticoids to suppress acute inflammation in autoimmune disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:19.210Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD)"}]},"trialDetails":[{"nctId":"NCT07159893","phase":"NA","title":"Inectolizumab With Steroid Optimization in Newly Treated NMOSD","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-09","conditions":"Neuromyelitis Optica, Autoimmune Diseases, Demyelinating Autoimmune Diseases, CNS","enrollment":25},{"nctId":"NCT07132398","phase":"PHASE3","title":"Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-01","conditions":"Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rapid-tapering glucocorticoids + Inebilizumab","genericName":"Rapid-tapering glucocorticoids + Inebilizumab","companyName":"Tianjin Medical University General Hospital","companyId":"tianjin-medical-university-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inebilizumab, a monoclonal antibody targeting plasmacytoid dendritic cells (pDCs), reduces pathogenic B cell and autoantibody production, combined with rapid-tapering glucocorticoids to suppress acute inflammation in autoimmune disease. Used for Anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}